Metilfenidato Generis

Methylphenidate Hydrochloride, the active ingredient in Metilfenidato Generis, is a central nervous system stimulant presented as an oral tablet for oral use. It treats attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults, improving focus, reducing impulsivity, and promoting wakefulness by enhancing neurotransmitter activity.

GNH USA supplies Metilfenidato Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality manufacturing standards and reliable distribution across global markets. The company adheres to EU regulations and rigorous quality control procedures.

Methylphenidate Hydrochloride is indicated for conditions within the central nervous system stimulant therapeutic class.

- Attention deficit hyperactivity disorder (ADHD): improves attention, reduces hyperactivity and impulsivity in children, adolescents, and adults. - Narcolepsy: decreases excessive daytime sleepiness and improves wakefulness. - ADHD in adults: enhances executive function and reduces distractibility.

Methylphenidate Hydrochloride may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach upset: nausea or abdominal discomfort.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, tachycardia, or arrhythmia. - Psychosis or severe mood changes: hallucinations, delusions, or manic episodes. - Severe allergic reaction: rash, swelling, or anaphylaxis.

When prescribing methylphenidate, clinicians should consider several safety precautions to minimize risk.

- Cardiovascular assessment: evaluate heart disease and blood pressure before initiating therapy. - Psychiatric history: monitor for mood swings, anxiety, or emergence of psychotic symptoms. - Growth monitoring in children: regularly track height and weight during treatment. - Potential for abuse: use only when clearly indicated and monitor for misuse. - Drug interactions: review concomitant medications for possible interactions. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Methylphenidate can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: may increase cardiovascular side effects. - Antihypertensive agents: methylphenidate may reduce their blood‑pressure‑lowering effect.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): may increase risk of serotonin syndrome. - Antacids: can alter absorption, requiring dose timing adjustments.